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Abstract
Antioxidant compounds are thought to prevent and treat diseases, especially 
cancer, under any circumstances. For this purpose, nature-based antioxidants 
nowadays are being commonly used to prevent and treat diseases. Indeed, phenolic 
compounds found in medicinal plants have opened a new horizon to prevent and 
treat diseases because of having antioxidant properties. However, some recent 
studies have reported that antioxidants are not absolute anticancer compounds 
and certain drugs have been reported to reduce levels of reactive oxygen species 
(ROS) in the cancer cells, i.e., their main action mechanism. It has been argued that 
increasing levels of ROS cause an increase in apoptosis rate and therefore can be 
considered an approach to treat fatal and hard-to-treat cancers. This chapter seeks 
to partly explain the role of ROS in progression or inhibition of cancer growth in 
addition to the role of antioxidants in preventing and treating this disease.
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1. Introduction
Cancer kills many people worldwide every year. Even in developed countries 
such as the United States, the rate of mortalities of cancer is high yet [1]. Although 
nowadays cancer therapy has improved, since complete recovery of cancer patients 
following a single treatment is quite difficult, a multidisciplinary approach com-
bined with surgery, chemotherapy, radiotherapy, and immunotherapy is usually 
utilized [2, 3]. However, some of these approaches cause several severe side effects 
in patients. Moreover, for many patients, current therapeutic approaches are 
successful only in delaying the time to disease progression rather than affecting 
long-term survival rates [4].
Many previous studies have shown that antioxidant supplementations are 
useful in cancer treatment [5]. An antioxidant substance in the cell is present at low 
concentrations and significantly reduces or prevents oxidation of the oxidizable 
substrates [6]. The researchers have evaluated highly complex antioxidant to protect 
the cells of the body against free radical damages [4]. However, some recent studies 
have reported that decreasing levels of cells’ oxidants, as reactive oxygen species 
(ROS) increase, causes increase in apoptosis rate and therefore can be considered an 
approach to treat fatal and hard-to-treat cancers.
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This chapter seeks to partly explain the role of ROS in progression or inhibition 
of cancer growth in addition to the role of antioxidants in preventing and treating 
this disease.
2. Oxidative stress in cancer
Among many factors that cause cancer, oxidative stress is one of the most 
principal and well-studied events that gives elevation to the conditions leading to 
tumor onset and progression [7, 8]. The oxidative stress and chronic inflammation 
processes are tightly coupled, and the failure to block these processes could result in 
genetic/epigenetic changes that drive the initiation of carcinogenesis [9]. Oxidative 
stress as an imbalance between the production and elimination of ROS causes 
excessive oxidative damage to macromolecules, cells, and tissues [10]. Oxidative/
nitrosative stress-induced peroxidation of membrane lipids can be very damaging 
because it leads to alterations in the biological properties of the membrane, such as 
the degree of fluidity, and can lead to inactivation of membrane-bound receptors or 
enzymes, which in turn may disable normal cellular function and increment tissue 
permeability [11]. The main outcome of oxidative/nitrosative stress is damage to 
lipids, nucleic acids, and proteins that can induce a variety of cellular responses 
through generation of reactive species or can compromise cell health and viability, 
finally causing cell death via apoptosis or necrosis [5, 12].
3. Reactive oxygen species (ROS)
Free radicals are known as “any chemical species capable of independent  
existence that contains one or more unpaired electrons” [13]. Reactive oxygen  
species (ROS) are free radicals which are correlated with the oxygen atom (O) or 
their equivalents and have stronger reactivity with other molecules, rather than 
with O2 [14]. When an imbalance between free radical and reactive metabolite 
production occurred, ROS are formed and can potentially exhibit a negative effect 
on the organism [15]. ROS is a collective term that includes the superoxide anion 
(O2
−), hydrogen peroxide (H2O2), and hydroxyl radical (HO˙) [14]. Radical  
formation in the body occurs via several mechanisms, involving both endogenous 
and environmental factors [11].
4. ROS in cancer
Cancer is a multistage process defined by initiation, promotion, and progres-
sion [16, 17], and oxidative stress interacts with all three stages. A little increase in 
the ROS level may cause a transient alteration in the cellular level, while a severe 
increase in ROS may result to irreversible oxidative damage and lead to cell death 
[18]. ROS can also promote carcinogenesis by inducing pro-oncogenic signaling 
pathways and DNA mutations. For instance, ROS may stimulate the phosphoryla-
tion of mitogen-activated protein kinase (MAPK), JUN N-terminal kinase (JNK) 
activation, cyclin D1 expression, and extracellular signal-regulated kinase (ERK), 
all of which are related to growth of tumor cells and survival [19].
Cancer cells generate ROS more abundantly than normal cells and cause 
elevated oxidative stress [20]. ROS can induce tumorigenicity and promote tumor 
progression via inducing DNA damage [21]. ROS induces gene mutations and 
structural changes in the DNA and results in DNA damage during the early stage 
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of tumorigenicity. In addition to, ROS can increase cell proliferation and decrease 
apoptosis via modifying second-messenger systems, causing abnormal gene expres-
sion, and blocking cell communications. Finally, oxidative stress can add DNA 
alterations to initiate cell population and promote cancer progression [22].
ROS might function as a double-edged sword (Figure 1). A moderate increase 
of ROS may promote cell proliferation and survival. However, when the increase of 
ROS reaches a certain level (the toxic threshold), it can overwhelm the antioxidant 
capacity of the cells and result in cell death [23]. It is long thought that antioxidants 
can remove the ROS that is produced in normal cellular processes and can protect 
cells from oxidative damage.
Reactive oxygen species (ROS) can promote cellular processes to cancer. In addi-
tion, they can induce apoptosis. Actually, ROS might function as a double-edged 
sword.
5. Antioxidants as a double-edged sword in cancer
Antioxidants as chemicals that interact with neutralized free radicals can 
prevent them from causing damages. Antioxidants divide to two main subgroups 
including enzymatic and nonenzymatic antioxidants. Catalase, superoxide dis-
mutase, and glutathione peroxidases are some of the most important enzymatic 
antioxidants [11]. Catalase (EC 1.11.1.6) as the first antioxidant enzyme was to be 
characterized and catalyzes conversion of hydrogen peroxide to water and oxygen. 
Superoxide dismutase (EC 1.15.1.1) is one of the most potent intracellular enzymatic 
antioxidants that catalyzes the conversion of superoxide anions to dioxygen and 
hydrogen peroxide. Glutathione peroxidases catalyze the oxidation of glutathione 
Figure 1. 
Relation between ROS actions with promoting and fighting cancer [23].
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at the direction of a hydroperoxide, which may be hydrogen peroxide or another 
species such as a lipid hydroperoxide.
Also, flavonoids, alkaloids, coumarins, carotenoids, and vitamins such as E, A, C 
(ascorbic acid), and D3 are some of the most important nonenzymatic antioxidants 
that are usually available in many natural products [24].
Antioxidants are known as free radical scavengers. Examples of dietary 
antioxidants include beta-carotene, lycopene, and vitamins A, C, and E (alpha-
tocopherol). Also, the mineral element selenium is often thought to be a dietary 
antioxidant. Moreover, natural compounds such as flavonoids, in particular ECGC 
and resveratrol, were shown to have a promising future as antioxidants and anticar-
cinogenic agents. These compounds can be consumed through fruits and vegetables 
[25]. In recent years, potential chemotherapeutic properties of antioxidants have 
been evaluated as a primary agent or in combination with an already established 
chemotherapeutic agent for different types of cancers. There is friction among 
researchers about the efficacy and safety of these complimentary treatments and 
their substantial role in protecting tumor cells from conventional therapy. The 
antioxidants can be endogenous or obtained exogenously as a part of a diet or as 
dietary supplements [11].
However, many natural compounds such as natural antioxidants display oppos-
ing properties in cancer cells, depending on their concentration (Figure 2). Some 
recent studies imply that much of late-stage cancer’s incurability may be due to its 
possession of too many antioxidants [14]. Actually, antioxidants may also cause 
direct damage to DNA and the cell. Watson recently wrote that time has come to 
seriously ask whether antioxidant use predominately causes rather than prevents 
cancer [26].
Figure 2. 
Natural antioxidants act as a double-edged sword in cancer [28].
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Some of these studies proposed that in some cases high-dose supplements of 
antioxidants may be related to health hazards. For example, high doses of beta-
carotene may enhance the risk of lung cancer in smokers. Prostate cancer can occur 
in dealing with high doses of vitamin E [27]. Antioxidant supplements may also 
interact with some medications. Based on these new concepts, the continuous use 
of certain antioxidants such as glutathione, superoxide dismutase, catalase, and 
thioredoxin may serve as a barrier to apoptosis, the main anticancer mechanism, 
through excessively reducing ROS [11].
The excessive damages via ROS can be associated with changes in mitochondrial 
membrane permeability, which result in cytochrome C release and apoptotic death. 
Against, cancer cells boost their anti-apoptotic mechanisms like a nuclear factor 
kappa-light-chain-enhancer of activated B cell (NFĸB) pathway to escape cell 
death [9]. Disruption of redox balance in cells causes activation of the transcription 
factors like nuclear factor erythroid 2-related factor 2 (Nrf2), NFĸB, and activator 
protein 1 (AP-1) as redox-sensitive transcription factors [28]. Nrf2 transcription 
factor is the major driver of antioxidant expression that leads to protection against 
DNA damage, endogenous and exogenous hazards, and consequent cancer initia-
tion [29, 30]. Nrf2 overexpresses in some types of human cancers including skin, 
head, and neck, squamous cell carcinoma, esophagus, pancreatic, gallbladder, pros-
tate, colorectal, breast, lung, and ovary. The cytoprotective properties of the Nrf2 
indicate that this pathway can be exploited by tumor cells to promote their survival 
[31, 32]. In the ROS-sensitive cancer cells, natural product-derived inhibitors of 
Nrf2 pathway can induce ROS that may result in cell death [28]. Many antioxidants 
such as polyphenols are significant groups of Nrf2 inhibitors.
Particularly in the case of cancer, the Nrf2 pathway has opposing properties: 
activating the pathway is vital for chemoprevention, but when the control is lost, 
it provides big consequences, so cancer cells result in fast proliferation, the escape 
of senescence and apoptosis, and resistance to chemotherapy and radiotherapy. 
Therefore, both activation and inhibition of Nrf2 activities can be beneficial [33]. 
As said above, natural products with antioxidant agents target Nrf2 pathway as an 
anticancer approach [28]. Several antioxidants may interact with other antioxidants 
that regenerate their primary properties; this mechanism is known as the “antioxi-
dant network.”
Opposing activities of natural products such as antioxidants in prevention and 
treatment of cancer depend on their concentration. At lower amounts, they often 
promote cells’ antioxidant capacity via activating Nrf2-dependent signaling and 
enhancing expression of ROS scavengers. However, higher concentrations can 
inhibit antioxidant defense and induce oxidative stress.
6. Antioxidants and tumorigenesis
Genetic alterations that promote tumor cause to produce endogenous antioxi-
dants [14]. In this process, Nrf2 is the main factor for the transactivation of involved 
genes in the maintenance of redox homeostasis [34]. As constitutive upregulation 
of Nrf2 factor has been reported for a variety of human cancer types, Nrf2 activity 
has been indicated to be necessary for proliferation of cancer cells [35–37], repro-
gramming of metabolism [38], chemoresistance [39], serine biosynthesis [36], as 
well as mRNA translation [37] in part through maintenance of redox homeostasis. 
Hi-activated pathway of Nrf2 increases the amount of cellular ROS scavengers. On 
the other hand, lowering stress burden via enhancing detoxifying force can affect 
the pathways that promote proliferation and growth [40, 41]. Blocking antioxidant 
activity in cancer cells decreases their ability to balance oxidative insult and might 
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result in cell death [42]. In addition to Nrf2, the transcription factor p53 has also 
been shown to suppress ROS accumulation via directly regulating the expression 
of a variety of antioxidant genes including SOD2, GPX1, and CAT [14, 39] and 
through the induction of the metabolic TIGAR gene (TP53-inducible glycolysis and 
apoptosis regulator) [14].
Oxidative stress can happen due to reduction in enzymatic antioxidant activities. 
Moreover, it can occur due to ionizing, radiation, chemotherapy, aging, shear stress, 
cytokines, and growth factor receptor interactions [14]. Antioxidants and oxida-
tive stress interact with the initiation, promotion, and progression of cancer [41]. 
Actually, the cell-damaging effects of free radicals can be balanced by antioxidants. 
Furthermore, as the fruits and vegetables are good sources of antioxidants, people 
who eat them more than others have a lower risk for various diseases such as heart 
and neurological diseases, and there is evidence that some types of vegetables and 
fruits in general protect against a number of cancers [43].
7. Advantages of using antioxidants as an anticancer approach
In addition to the standard anticancer treatment options such as chemotherapy, 
radiotherapy, and surgery, several natural products due to their antioxidant activi-
ties have been identified to have a potential for cancer prevention [44] and treat-
ment [45].
In radiotherapy and chemotherapy, ROS and free radicals partly cause various 
adverse effects [46]. ROS generation causes various tissue or organ injuries; for 
example, doxorubicin and other anthracycline antibiotics are known to lead to car-
diotoxicity [47]; cisplatin and other platinums lead to nephrotoxicity, ototoxicity, 
and peripheral neuropathy [48]; bleomycin leads to lung injury [49]; and alkylating 
agents cause DNA damage of drug-treated cells [50]. Tissue or organ injuries may 
also induce carcinogenesis [51]. Many previous studies reported that using antioxi-
dants with these gold standard methods can significantly decrease these cellular 
damages. For instance, in one study that is reported by Askua et al., among the 49 
studies, 46 examined the reduction of adverse effects by antioxidant supplementa-
tion; in 34 trials, possible reductions in chemotoxicities or radiotoxicities using 
antioxidant supplementation were reported; and only 1 RCT, using vitamin A, 
reported that supplementation possibly increased chemoinduced toxicities. The 
remaining 11 studies reported no significantly difference in toxicities between  
control and supplementation groups [51]. Further, the results of the Shanghai 
Breast Cancer Survival Study showed that consumption of multivitamins or vita-
mins such as C and E within 6 months of breast cancer diagnosis correlated with 
18% decreased mortality and 22% decreased recurrence rate [52]. In addition, the 
Life After Cancer Epidemiology (LACE) cohort study results on effects of vitamins 
E and C and combination of carotenoid supplementation in breast cancer showed 
that vitamins E and C intake before and after breast cancer diagnosis was related to 
22% reduced risk of all-cause mortality, 32% decreased breast cancer mortality, and 
20% decreased recurrence risk [53].
8. Future therapeutic perspectives
We are approaching a new era wherein ROS biology and their effects in the 
physiopathology of cancer may be dissected with unprecedented detail, bringing 
potential therapeutic benefits derived from selective manipulations of cancer redox 
balance to be uncovered, paving the way to novel and exciting investigations in the 
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fight against cancer [6]. Owing to the crucial roles of cancer stem cells in tumor 
initiation, disease recurrence, and drug resistance, the potential of using a redox-
modulating strategy to eliminate this subpopulation of malignant cells could have 
major implications in cancer treatment. Redox adaptation is an important concept 
that, to a large degree, explains the mechanisms by which cancer cells survive under 
persistent endogenous ROS stress and become resistant to certain anticancer agents. 
Targeting these biochemical properties of cancer cells with redox-modulating 
strategies is a feasible therapeutic approach that may enable therapeutic selectivity 
and overcome drug resistance. Also, Nrf2 is arguably the most important regulator 
of the expression of molecules that have antioxidant functions within the cell [13]. 
Nrf2 controls the expression of these enzymes and is considered to be a master 
regulator of intracellular antioxidant responses. An increased Nrf2 activity in 
normal cells is protective and beneficial against oxidative stress, but cancer cells 
harness the ability of Nrf2 to survive under stress conditions [14]. Nrf2 activators, 
such as bardoxolone methyl CDDO-Me, have shown anticancer activity preclini-
cally and are currently being tested in clinical trials [15]. Moreover, glutathione 
(GSH) metabolism seems to be the main target of currently used anticancer drugs. 
Combinations of GSH inhibitors (or other antioxidant inhibitors) with radiother-
apy or chemotherapeutic drugs that cause cell death induced by oxidative stress may 
prove to be useful for more effectively killing cancer cells.
9. Conclusion
ROS/RNS protection in cancer is an important issue that attracts many scientists 
in recent years to discover the mechanism of action of various antioxidants. The 
idea that fruit and vegetable consumption alone is associated with a decreased risk 
of cancer is yet to be determined. This chapter shows that antioxidants, as previ-
ously reported, contribute to prevent and treat many types of cancer, but their 
anticancer effects are not absolute and depend on the time, amount, and conditions 
of their administration to treat different cancers. It is important that physicians 
make an integrated decision, based on the following consideration: (1) the back-
ground and state of the patient, (2) the antioxidant dosage and types, and (3) type 
of cancer and antitumor therapy. In addition, it is necessary to examine the safety 
and viability of antioxidants in pathological conditions and cancer therapy and 
that trials be performed with a single regimen, single type of cancer, and single 
antioxidant.
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